Literature DB >> 25827402

3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.

Robert L Hudkins1, Nadine C Becknell2, Jacquelyn A Lyons2, Lisa D Aimone2, Mark Olsen2, R Curtis Haltiwanger2, Joanne R Mathiasen2, Rita Raddatz2, John A Gruner2.   

Abstract

A novel series of 3,4-diaza-bicyclo[4.1.0]hept-4-en-2-ones were designed and synthesized as H3R analogs of irdabisant 6. Separation of the isomers, assignment of the stereochemistry by crystallography, and detailed profiling of diastereomers 25 and 26 led to the identification of (1R,6S)-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)propoxy]phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one 25 as a potential second generation H3R candidate. Diastereomer 25 had high H3R binding affinity, excellent selectivity, displayed potent H3R functional antagonism and robust wake-promoting activity in vivo, and showed acceptable pharmacokinetic and pharmaceutical profiles for potential further development.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CEP-26401; H(3) inverse agonist; Histamine H(3) receptor; Irdabisant; Pyridazin-3-one; Sleep-wake

Mesh:

Substances:

Year:  2015        PMID: 25827402     DOI: 10.1016/j.ejmech.2015.03.054

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  1 in total

1.  Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Authors:  Anne C Baakman; Rob Zuiker; Joop M A van Gerven; Nicholas Gross; Ronghua Yang; Michael Fetell; Ari Gershon; Yossi Gilgun-Sherki; Edward Hellriegel; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2019-03-14       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.